Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Pharma Stocks Weighed Down by Competition, Generic Pressure

Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note, drug companies may find it a bit difficult to justify their high prices.

    Can New Approvals Help Mylan Stock Turn Around in 2018?

    Mylan (MYL) faced challenging conditions in 2017 but 2018 is expected to be better driven by new product launches.

      Pharmaceutical Industry Outlook - March 2018

      The year 2017 was rewarding for pharma and biotech stocks, with the sector witnessing some positive developments that led to a much-awaited recovery.

        Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss

        Mylan???s (MYL) mixed Q4 results show earnings beat but revenues miss on pricing pressure and weak EpiPen sales.

          Will Mylan (MYL) Disappoint Investors This Earnings Season?

          During the Q4 earnings call, investors are expected to remain focused on the performance of Mylan's (MYL) EpiPen, newly launched drugs and the progress of the biosimilars pipeline.

            United Therapeutics (UTHR) Q4 Earnings Decline on High Costs

            United Therapeutics' (UTHR) earnings per share decline in Q4 due to higher operating costs. Shares sink almost 10%.

              Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4

              Momenta (MNTA) delivers better-than-expected fourth-quarter results on the back of an upfront payment from CSL.

                Teva's Problems Continue to Mount With No Relief in Sight

                Teva (TEVA) faces significant challenges including rapid erosion in sales of Copaxone and pricing erosion in the U.S. generics business.

                  J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)

                  J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

                    Ryan McQueeney headshot

                    Here's Why Teva Pharma Stock Is Soaring Today

                    Shares of Teva Pharmaceuticals (TEVA) gained more than 10% in early morning trading Thursday after news emerged Wednesday that Warren Buffett's Berkshire Hathaway (BRK.B) took a massive stake in the struggling drugmaker during the fourth quarter.

                      J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment

                      J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

                        Teva Stock Falls as Novartis Brings Another Copaxone Generic

                        Teva's (TEVA) shares fall as Novartis launches the second generic version of the 40 mg formulation of Copaxone

                          Generic Drugmakers to Dump as Teva's Woes Continue in 2018

                          The generic industry is facing several challenges pulling down several companies including Teva (TEVA).

                            Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View

                            Teva's (TEVA) fourth-quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate.

                              Teva (TEVA) Q4 Earnings & Sales Beat, 2018 View Disappoints

                              Teva's (TEVA) fourth quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate. Stock crashes in pre-market trading.

                                What's in the Cards for Teva (TEVA) This Earnings Season?

                                Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone will hurt sales in the Specialty segment.

                                  Teva Completes Sale of Women's Health Segment for $703M

                                  Teva Pharmaceutical (TEVA) sells woman health specialty products for cash consideration of $703 million.

                                    Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb

                                    Amgen's (AMGN) antibody Aimovig meets all primary and secondary endpoints in a phase IIIb study on patients with episodic migraine, who have failed multiple prior preventive treatments.

                                      Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies

                                      Teva's (TEVA) two phase III studies evaluating the subcutaneous formulation of its asthma injection, Cinqair (reslizumab) fail to meet primary endpoints.

                                        Teva's Trisenox Gets FDA Approval as First-Line Treatment

                                        Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

                                          Parkinson's Disease Space Again Under Spotlight This Week

                                          Parkinson's Disease emerges a lucrative area in want of curative therapies in the space. To this end, many players work toward launching new treatments in the market.

                                            AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU

                                            AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.

                                              Momenta & Mylan to Initiate Trial on Biosimilar of Eylea

                                              Momenta (MNTA), in collaboration with Mylan (MYL), plans to initiate a trial of M710, a proposed biosimilar of leading ophthalmology drug Eylea, in the first half of 2018.

                                                New Strong Sell Stocks for December 20th

                                                Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                                  Teva's Migraine Candidate Gets Priority Review From FDA

                                                  Teva's (TEVA) biologics license application (BLA) seeking approval for fremanezumab as a preventive treatment for migraine gets priority review from FDA